<DOC>
	<DOCNO>NCT00236795</DOCNO>
	<brief_summary>The purpose study compare contraceptive efficacy safety transdermal patch Triphasil .</brief_summary>
	<brief_title>A Study Efficacy Safety With Transdermal Contraceptive System Versus Triphasil .</brief_title>
	<detailed_description>This open-label , multicenter , worldwide study evaluate contraceptive efficacy , safety , cycle control , compliance , subject satisfaction transdermal patch compare Triphasil . Fourteen hundred healthy woman receive study medication either 6 13 cycle . The first 33 % subject ( ~265 transdermal patch subject 200 Triphasil subject ) expect complete 13 cycle medication . All subsequent subject expect complete 6 cycle . The ratio subject assign transdermal patch arm study Triphasil arm 4:3 . At admission ( Visit 1 ) study drug ( plus 3 reserve patch ) , diary card subject instruction Cycle 1 dispense . The first patch apply Triphasil pill take first day menses . Study medication diary card issue day 28 Cycles 1 ( Visit 2 ) 3 ( Visit 3 ) , continue 13 cycle receive study drug ( plus 3 reserve patch ) day 28 Cycles 6 ( Visit 4 ) 9 ( Visit 5 ) . Diary card empty medication package collect every visit . Final visit day 28 Cycles 6 9 . Diary card information use record compliance bleed information ( assess cycle control ) . Contraceptive efficacy assess mean Pearl Index life table analysis ( gross cumulative probability pregnancy ) . Safety evaluation base adverse event , collect throughout study , change physical examination , gynecologic examination , vital sign , laboratory result prestudy final visit . A transdermal patch , contain 6 mg NGM 0.75 mg EE , deliver 250 ug NGM 25 ug EE 24 hour 7 day , worn 1 week replace 3 consecutive weeks.The fourth week patch-free . A Triphasil pill take 28 consecutive day time day .</detailed_description>
	<mesh_term>Norelgestromin</mesh_term>
	<mesh_term>Ethinyl Estradiol-Norgestrel Combination</mesh_term>
	<mesh_term>Ethinyl estradiol , levonorgestrel drug combination</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<criteria>Healthy , nonpregnant woman regular menstrual cycle sexually active risk pregnancy acceptable body mass index ( BMI ) last term pregnancy least 42 day prior , nonlactating , 1 normal menstrual cycle since sit BP &lt; 140mmHg/ &lt; 90mmHg 1 normal menstrual cycle since removal IUD norplant agreement use study drug contraception 13 cycle , except backup contraception require disease protection patch detachment agree use systemic steroid medication Presence , history , hereditary predisposition risk deep vein thrombophlebitis thromboembolic disorder cerebral vascular coronary artery disease , hypertension , severe migraine liver tumor result estrogencontaining product diabetes mellitus cholestatic jaundice , liver renal disease abnormal PAP smear undiagnosed abnormal vaginal bleeding thyroid disorder dermal hypersensitivity carcinoma breast , genital tract estrogendependent neoplasia receive depot hormone injection within prior 6 month smoke woman 35 year age .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>contraception</keyword>
	<keyword>hormonal contraception</keyword>
	<keyword>oral contraception</keyword>
	<keyword>steroid , ethinyl estradiol , horgestimate , levonorgestrel contraception</keyword>
	<keyword>transdermal .</keyword>
</DOC>